XPA (P23025) variants and mutations
XPA (also known as P23025) is a human protein-coding gene encoding a DNA repair protein complementing XP-A cells protein. It verifies bulky DNA lesions and organizes the nucleotide-excision-repair machinery around damaged sites. Biallelic loss-of-function variants cause xeroderma pigmentosum group A with extreme ultraviolet sensitivity, early skin cancers, and often progressive neurologic disease. This analysis covers 558 XPA variants and mutations. Of these, 86% have computational variant effect predictions. Disease context includes xeroderma pigmentosum, xeroderma pigmentosum group A, and Xeroderma pigmentosum complementation group A. Example XPA variants include M1T, A2V, and A3S.
Variant analysis overview
- Gene: XPA
- Protein: P23025
- UniProt accession: P23025
- Organism: Homo sapiens
- Variants analyzed: 558
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 338 unspecified-consequence records; 100 missense variants; 31 frameshift variants; 6 stop-gained variants; 65 synonymous variants; 11 in-frame deletions; 2 in-frame insertions; 4 splice-region variants; 1 substitution
- Prediction scores: 479 variants have prediction scores (86% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: xeroderma pigmentosum, xeroderma pigmentosum group A, Xeroderma pigmentosum complementation group A, basal cell carcinoma, non-melanoma skin carcinoma, skin cancer, hereditary disease, hypothyroidism, neurodegenerative disease, colorectal adenocarcinoma, endometrial endometrioid adenocarcinoma, prostate adenocarcinoma.
Protein structure and variant hotspots
- Protein features: 4 binding sites; 2 post-translational modification sites.
- PTM context: 3 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable XPA variants
Examples include M1T, A2V, A3S, A3V, A4V, D5A, D5E, D5N. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1T (p.Met1Thr), rs1253496792, ClinGen CA374188668, ClinVar RCV000666994, MetaLR 0.12, MetaSVM -0.89, Likely pathogenic, Xeroderma pigmentosum group A
- A2V (p.Ala2Val), ExAC rs760890900, gnomAD rs760890900, REVEL 0.19, CADD 21.50
- A3S (p.Ala3Ser), Ensembl rs1564052844, REVEL 0.03, CADD 8.17
- A3V (p.Ala3Val), rs1440375480, NCI-TCGA Cosmic COSV1009, TOPMed rs1440375480, gnomAD rs1440375480, REVEL 0.03, CADD 15.00, Variant assessed as somatic; moderate impact.
- A4V (p.Ala4Val), TOPMed rs973122222, gnomAD rs973122222, REVEL 0.04, CADD 9.42, Uncertain significance, Inborn genetic diseases
- D5A (p.Asp5Ala), TOPMed rs905489379, gnomAD rs905489379, REVEL 0.07, CADD 2.66
- D5E (p.Asp5Glu), 1000Genomes rs553043532, ExAC rs553043532, TOPMed rs553043532, gnomAD rs553043532, REVEL 0.04, CADD 0.65, Likely benign
- D5N (p.Asp5Asn), rs574504791, ClinGen CA5148943, ClinVar RCV003033143, 1000Genomes rs574504791, REVEL 0.11, CADD 17.20, Uncertain significance, not provided
- D5V (p.Asp5Val), TOPMed rs905489379, gnomAD rs905489379
- D5Y (p.Asp5Tyr), rs574504791, ClinGen CA5148942, ClinVar RCV001168275, ClinVar RCV002558662, REVEL 0.09, CADD 21.20, Uncertain significance, not provided; Xeroderma pigmentosum group A
- G6A (p.Gly6Ala), gnomAD rs1829086621, REVEL 0.05, CADD 0.03
- G6E (p.Gly6Glu), gnomAD rs1829086621, REVEL 0.05, CADD 0.03
- G6R (p.Gly6Arg), rs200218050, NCI-TCGA Cosmic COSV6430, ExAC rs200218050, REVEL 0.05, CADD 7.68, Variant assessed as somatic; moderate impact.
- G6W (p.Gly6Trp), rs200218050, NCI-TCGA Cosmic COSV6430, ExAC rs200218050, REVEL 0.12, CADD 16.90, Variant assessed as somatic; moderate impact.
- A7G (p.Ala7Gly), TOPMed rs1228453951, gnomAD rs1228453951, REVEL 0.03, CADD 5.52, Uncertain significance
- A7S (p.Ala7Ser), ExAC rs776601238, TOPMed rs776601238, gnomAD rs776601238, REVEL 0.05, CADD 0.01, Uncertain significance
- A7T (p.Ala7Thr), rs776601238, ClinGen CA5148938, ClinVar RCV002606455, ExAC rs776601238, REVEL 0.03, CADD 0.05, Uncertain significance, not provided
- A7V (p.Ala7Val), rs1228453951, ClinGen CA374188634, ClinVar RCV002255909, TOPMed rs1228453951, REVEL 0.05, CADD 5.96, Uncertain significance, Xeroderma pigmentosum
- L8W (p.Leu8Trp), TOPMed rs1276237668
- P9A (p.Pro9Ala), ExAC rs746677235, TOPMed rs746677235, gnomAD rs746677235, REVEL 0.09, CADD 2.36
- P9L (p.Pro9Leu), ExAC rs779912540, TOPMed rs779912540, gnomAD rs779912540, REVEL 0.05, CADD 9.07
- P9S (p.Pro9Ser), ExAC rs746677235, TOPMed rs746677235, gnomAD rs746677235, REVEL 0.07, CADD 4.12
- E10A (p.Glu10Ala), ExAC rs755452842, TOPMed rs755452842, gnomAD rs755452842, REVEL 0.08, CADD 20.10
- E10D (p.Glu10Asp), TOPMed rs1432674891, gnomAD rs1432674891, REVEL 0.12, CADD 15.10
- E10G (p.Glu10Gly), ExAC rs755452842, TOPMed rs755452842, gnomAD rs755452842, REVEL 0.06, CADD 24.20, Uncertain significance, Inborn genetic diseases
- E10K (p.Glu10Lys), rs771752416, NCI-TCGA Cosmic COSV6430, ExAC rs771752416, gnomAD rs771752416, AlphaMissense 0.09, MetaLR 0.11, Variant assessed as somatic; moderate impact.
- E10Q (p.Glu10Gln), ExAC rs771752416, gnomAD rs771752416, REVEL 0.07, AlphaMissense 0.09
- A11P (p.Ala11Pro), gnomAD rs1326902057, REVEL 0.06, CADD 12.30
- A13G (p.Ala13Gly), ExAC rs778123456, gnomAD rs778123456, REVEL 0.04, CADD 22.60
- A13P (p.Ala13Pro), ExAC rs754275652, TOPMed rs754275652, gnomAD rs754275652, REVEL 0.04, CADD 15.70
- A13T (p.Ala13Thr), ExAC rs754275652, TOPMed rs754275652, gnomAD rs754275652, REVEL 0.05, CADD 14.90
- A13V (p.Ala13Val), ExAC rs778123456, gnomAD rs778123456, REVEL 0.06, CADD 21.00
- L14F (p.Leu14Phe), TOPMed rs1829084223, gnomAD rs1829084223, REVEL 0.10, CADD 4.97
- L14I (p.Leu14Ile), Ensembl rs2131411639
- Q16E (p.Gln16Glu), TOPMed rs1829084132
- Q16R (p.Gln16Arg), rs756527969, ClinGen CA5148927, ClinVar RCV001168274, ExAC rs756527969, REVEL 0.04, CADD 13.60, Uncertain significance, Xeroderma pigmentosum group A
- P17H (p.Pro17His), NCI-TCGA Cosmic COSV6430, REVEL 0.14, CADD 20.80, Variant assessed as somatic; moderate impact.
- A18V (p.Ala18Val), TOPMed rs1829083913
- E19G (p.Glu19Gly), Ensembl rs1829083820, REVEL 0.13, CADD 23.40
- P21L (p.Pro21Leu), gnomAD rs1453891229, REVEL 0.19, CADD 24.90
- A22G (p.Ala22Gly), TOPMed rs1829083218, REVEL 0.27, CADD 25.50
- A22S (p.Ala22Ser), TOPMed rs1829083313, gnomAD rs1829083313, REVEL 0.20, CADD 22.70, Uncertain significance, Inborn genetic diseases
- S23* (p.Ser23Ter), TOPMed rs1179193179, gnomAD rs1179193179, CADD 36.00, Likely pathogenic
- S23L (p.Ser23Leu), rs1179193179, NCI-TCGA Cosmic COSV1009, TOPMed rs1179193179, gnomAD rs1179193179, REVEL 0.11, CADD 22.30, Likely pathogenic
- S23P (p.Ser23Pro), TOPMed rs1213814173, gnomAD rs1213814173, REVEL 0.17, CADD 22.70
- V24E (p.Val24Glu), 1000Genomes rs199616261, ExAC rs199616261, TOPMed rs199616261, gnomAD rs199616261, REVEL 0.10, CADD 22.80
- R25L (p.Arg25Leu), TOPMed rs1033405989, gnomAD rs1033405989, REVEL 0.19, CADD 24.10
- R25P (p.Arg25Pro), TOPMed rs1033405989, gnomAD rs1033405989
- R25Q (p.Arg25Gln), TOPMed rs1033405989, gnomAD rs1033405989, REVEL 0.18, CADD 31.00
- A26P (p.Ala26Pro), rs766444854, ClinGen CA5148922, ClinVar RCV002259221, ExAC rs766444854, REVEL 0.25, CADD 25.80, Uncertain significance, Xeroderma pigmentosum
- S27G (p.Ser27Gly), gnomAD rs1274100357, REVEL 0.12, CADD 22.80
- I28F (p.Ile28Phe), ExAC rs776656098, gnomAD rs776656098, REVEL 0.12, CADD 22.60
- I28M (p.Ile28Met), gnomAD rs1373166407, REVEL 0.09, CADD 19.10
- I28N (p.Ile28Asn), TOPMed rs953257350
- E29D (p.Glu29Asp), TOPMed rs1318340274, gnomAD rs1318340274, REVEL 0.21, CADD 23.70
- E29G (p.Glu29Gly), ExAC rs768702767, TOPMed rs768702767, gnomAD rs768702767, REVEL 0.39, CADD 32.00
- R30Q (p.Arg30Gln), rs760613920, ClinGen CA5148918, ClinVar RCV002257195, ExAC rs760613920, REVEL 0.26, CADD 32.00, Uncertain significance, Xeroderma pigmentosum
- R30W (p.Arg30Trp), Ensembl rs777449731, REVEL 0.44, CADD 32.00
- K31N (p.Lys31Asn), TOPMed rs1829080164, gnomAD rs1829080164, REVEL 0.11, CADD 19.50
- R34W (p.Arg34Trp), TOPMed rs1424881212, gnomAD rs1424881212, REVEL 0.34, CADD 32.00
- L36R (p.Leu36Arg), rs1829079091, ClinGen CA374188466, ClinVar RCV004485580, TOPMed rs1829079091, REVEL 0.45, CADD 32.00, Uncertain significance, Inborn genetic diseases
- M37K (p.Met37Lys), rs1479271208, ClinGen CA374188460, ClinVar RCV003237458, gnomAD rs1479271208, REVEL 0.30, CADD 25.20, Uncertain significance, not provided
- L38P (p.Leu38Pro), TOPMed rs1435795217, gnomAD rs1435795217, REVEL 0.76, CADD 33.00
- R39C (p.Arg39Cys), TOPMed rs1297020806, gnomAD rs1297020806, REVEL 0.45, CADD 32.00
- R39H (p.Arg39His), gnomAD rs1328849329, REVEL 0.27, CADD 25.00
- R39P (p.Arg39Pro), gnomAD rs1328849329
- Q40R (p.Gln40Arg), Ensembl rs1829077998, REVEL 0.13, CADD 25.00
- A41S (p.Ala41Ser), Ensembl rs1829077718, REVEL 0.26, CADD 24.90
- A41V (p.Ala41Val), rs778289269, ClinGen CA5148912, ClinVar RCV001761804, ClinVar RCV002540729, REVEL 0.48, CADD 33.00, Uncertain significance, not provided; Xeroderma pigmentosum group A
- R42G (p.Arg42Gly), TOPMed rs905874399, gnomAD rs905874399, REVEL 0.23, CADD 25.40, Likely benign
- R42P (p.Arg42Pro), TOPMed rs1829077192, gnomAD rs1829077192, REVEL 0.30, CADD 27.60
- A45D (p.Ala45Asp), TOPMed rs1438104861, gnomAD rs1438104861, REVEL 0.15, CADD 23.70
- A45S (p.Ala45Ser), NCI-TCGA TCGA novel, REVEL 0.13, CADD 19.70, Variant assessed as somatic; moderate impact.
- A45T (p.Ala45Thr), TOPMed rs1346748246, REVEL 0.10, CADD 22.20
- A45V (p.Ala45Val), TOPMed rs1438104861, gnomAD rs1438104861, REVEL 0.12, CADD 23.70
- R46L (p.Arg46Leu), rs1217308115, ClinGen CA374188405, ClinVar RCV002261870, TOPMed rs1217308115, REVEL 0.25, CADD 28.90, Uncertain significance, not provided
- R46W (p.Arg46Trp), gnomAD rs1277630830, REVEL 0.29, CADD 32.00, Uncertain significance, Inborn genetic diseases
- P47H (p.Pro47His), gnomAD rs1829075986, REVEL 0.32, CADD 32.00
- P47R (p.Pro47Arg), rs2490246360, ClinGen CA2697557943, ClinVar RCV003563816, REVEL 0.35, CADD 31.00, Pathogenic
- Y48N (p.Tyr48Asn), ExAC rs770415986, gnomAD rs770415986, REVEL 0.19, CADD 25.60
- S49L (p.Ser49Leu), TOPMed rs1374751849, gnomAD rs1374751849, REVEL 0.12, CADD 24.40
- S49P (p.Ser49Pro), Ensembl rs1829075688
- S49W (p.Ser49Trp), TOPMed rs1374751849, gnomAD rs1374751849, REVEL 0.20, CADD 28.80
- A50T (p.Ala50Thr), TOPMed rs1300025362, gnomAD rs1300025362, REVEL 0.08, CADD 22.30
- A50V (p.Ala50Val), TOPMed rs1443173071, gnomAD rs1443173071, REVEL 0.08, CADD 22.90
- T51M (p.Thr51Met), ExAC rs778315426, TOPMed rs778315426, gnomAD rs778315426, REVEL 0.12, CADD 23.50, Uncertain significance
- T51R (p.Thr51Arg), rs778315426, ClinGen CA5148908, ClinVar RCV003237457, ClinVar RCV005772220, REVEL 0.08, CADD 22.80, Uncertain significance, not provided; Inborn genetic diseases
- A52V (p.Ala52Val), gnomAD rs1205446893, REVEL 0.04, CADD 23.20
- A54E (p.Ala54Glu), Ensembl rs1044632915, REVEL 0.22, CADD 24.00
- A54T (p.Ala54Thr), ExAC rs756578830, gnomAD rs756578830, REVEL 0.14, CADD 24.00
- A55S (p.Ala55Ser), 1000Genomes rs577348290, ExAC rs577348290, gnomAD rs577348290, REVEL 0.03, CADD 17.50
- T56I (p.Thr56Ile), ExAC rs781569303, gnomAD rs781569303, REVEL 0.06, CADD 22.90
- G57R (p.Gly57Arg), rs558921404, ClinGen CA5148904, ClinVar RCV004485581, 1000Genomes rs558921404, REVEL 0.25, CADD 26.60, Uncertain significance, Inborn genetic diseases
- G57V (p.Gly57Val), Ensembl rs950281583, REVEL 0.19, CADD 33.00
- G58=, NCI-TCGA Cosmic COSV6430, Variant assessed as somatic; low impact.
- G58D (p.Gly58Asp), TOPMed rs1365252970, gnomAD rs1365252970, REVEL 0.16, CADD 24.90
- G58V (p.Gly58Val), TOPMed rs1365252970, gnomAD rs1365252970
- M59V (p.Met59Val), TOPMed rs1459118524, gnomAD rs1459118524, REVEL 0.08, CADD 0.36
- A60D (p.Ala60Asp), NCI-TCGA Cosmic COSV6430, Variant assessed as somatic; moderate impact.
- N61S (p.Asn61Ser), gnomAD rs1185357926, REVEL 0.04, CADD 14.00
- V62I (p.Val62Ile), TOPMed rs1476014427, gnomAD rs1476014427, REVEL 0.06, CADD 16.40
- V62L (p.Val62Leu), TOPMed rs1476014427, gnomAD rs1476014427, REVEL 0.06, CADD 18.00
- A64T (p.Ala64Thr), NCI-TCGA Cosmic COSV6430, Variant assessed as somatic; moderate impact.
- A65P (p.Ala65Pro), TOPMed rs1487243894, gnomAD rs1487243894
- A65T (p.Ala65Thr), rs1487243894, NCI-TCGA Cosmic COSV6430, TOPMed rs1487243894, gnomAD rs1487243894, REVEL 0.07, CADD 15.30, Variant assessed as somatic; moderate impact.
- A65V (p.Ala65Val), gnomAD rs1262442661
- K67E (p.Lys67Glu), ExAC rs767594576, TOPMed rs767594576, gnomAD rs767594576, REVEL 0.32, CADD 25.90
- K67N (p.Lys67Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K67R (p.Lys67Arg), gnomAD rs1321202142, REVEL 0.11, CADD 20.10
- I68T (p.Ile68Thr), rs368468515, ClinGen CA5148884, ClinVar RCV001508631, ESP rs368468515, REVEL 0.06, CADD 21.90, Uncertain significance, not provided
- I69S (p.Ile69Ser), ExAC rs755315448, TOPMed rs755315448, gnomAD rs755315448, REVEL 0.44, CADD 24.20, Uncertain significance
- I69T (p.Ile69Thr), rs755315448, ClinGen CA5148883, ClinVar RCV004485582, ExAC rs755315448, REVEL 0.28, CADD 22.60, Uncertain significance, Inborn genetic diseases
- I69V (p.Ile69Val), gnomAD rs1235353864, REVEL 0.06, CADD 18.20
- T71I (p.Thr71Ile), ExAC rs747326646, gnomAD rs747326646, REVEL 0.36, CADD 25.80
- T71R (p.Thr71Arg), ExAC rs747326646, gnomAD rs747326646, REVEL 0.37, CADD 25.30
- G72V (p.Gly72Val), Ensembl rs2131406145
- G73E (p.Gly73Glu), NCI-TCGA Cosmic COSV6430, Variant assessed as somatic; moderate impact.
- G74S (p.Gly74Ser), rs780390664, ClinGen CA5148880, ClinVar RCV003286925, ExAC rs780390664, REVEL 0.81, CADD 25.60, Uncertain significance, Inborn genetic diseases
- F75L (p.Phe75Leu), gnomAD rs1364642460, REVEL 0.73, CADD 23.90
- I76V (p.Ile76Val), Ensembl rs1564050421, REVEL 0.06, CADD 21.30
- E78K (p.Glu78Lys), Ensembl rs1828959137
- E79* (p.Glu79Ter), rs1554702608, ClinGen CA374188116, ClinVar RCV000671257, Ensembl rs1554702608, Likely pathogenic
- E80* (p.Glu80Ter), rs2490237785, ClinGen CA374188102, ClinVar RCV003579166, Pathogenic
- E81D (p.Glu81Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E81K (p.Glu81Lys), Ensembl rs1828958728, REVEL 0.04, CADD 20.20
- E84* (p.Glu84Ter), NCI-TCGA Cosmic COSV6430, Variant assessed as somatic; high impact.
- E84Q (p.Glu84Gln), TOPMed rs1331929521, Uncertain significance, not specified
- Q85* (p.Gln85Ter), rs765361885, ClinGen CA374188027, ClinVar RCV001555786, ExAC rs765361885, CADD 34.00, Pathogenic
- Q85E (p.Gln85Glu), ExAC rs765361885, TOPMed rs765361885, gnomAD rs765361885, REVEL 0.06, CADD 6.04, Pathogenic
- K86T (p.Lys86Thr), Ensembl rs1828957829, REVEL 0.04, CADD 15.20
- G88R (p.Gly88Arg), rs2490237639, ClinGen CA374187989, ClinVar RCV003267611, REVEL 0.06, CADD 19.50, Uncertain significance, Inborn genetic diseases
- K89T (p.Lys89Thr), rs2490237610, ClinGen CA374187971, ClinVar RCV002757041, Uncertain significance, Inborn genetic diseases
- V91F (p.Val91Phe), Ensembl rs1828957440, REVEL 0.28, CADD 23.80
- H92Y (p.His92Tyr), ExAC rs752620949, gnomAD rs752620949, REVEL 0.17, CADD 25.50
- P94L (p.Pro94Leu), UniProt VAR 007727, Pathogenic, in XP-A
- G95E (p.Gly95Glu), TOPMed rs1371674347, gnomAD rs1371674347, REVEL 0.31, CADD 25.70
- G95R (p.Gly95Arg), rs2490237534, ClinGen CA374187933, ClinVar RCV003557460, ClinVar RCV004574099, REVEL 0.28, CADD 35.00, Pathogenic/Likely pathogenic, not provided; Xeroderma pigmentosum; Xeroderma pigmentosum group A
- G95G (p.Gly95Gly), rs530809213, gnomAD 9-97689638-T-A, CADD 12.40
- G95V (p.Gly95Val), gnomAD 9-97689639-C-A, REVEL 0.30, MetaLR 0.27
- P96A (p.Pro96Ala), Ensembl rs573834910, REVEL 0.46, CADD 25.70
- P96P (p.Pro96Pro), rs1310920247, gnomAD 9-97689635-A-G, CADD 7.25
- P96L (p.Pro96Leu), gnomAD 9-97689636-G-A, REVEL 0.58, MetaLR 0.46
- P96H (p.Pro96His), gnomAD 9-97689636-G-T, REVEL 0.55, MetaLR 0.46
- P96S (p.Pro96Ser), gnomAD 9-97689637-G-A, REVEL 0.45, MetaLR 0.46
- V97I (p.Val97Ile), rs10983315, ClinGen CA5148848, ClinVar RCV000903901, ClinVar RCV001168273, REVEL 0.14, CADD 22.10, Benign/Likely benign, Xeroderma pigmentosum group A; not provided
- V97L (p.Val97Leu), gnomAD 9-97689634-CA-C, CADD 22.10
- M98L (p.Met98Leu), TOPMed rs1339290732, REVEL 0.18, CADD 16.30
- M98T (p.Met98Thr), Ensembl rs1828822299, REVEL 0.54, CADD 23.60
- M98V (p.Met98Val), rs1339290732, ClinGen CA374187903, ClinVar RCV003154666, ClinVar RCV003164878, REVEL 0.20, CADD 17.90, Conflicting interpretations, Inborn genetic diseases; Ovarian cancer
- M98R (p.Met98Arg), gnomAD 9-97689630-A-C, REVEL 0.56, MetaLR 0.42
- M98W (p.Met98Trp), gnomAD 9-97689631-TA-T, CADD 23.20
- D101M (p.Asp101Met), gnomAD 9-97689618-TAATC-, CADD 33.00
- D101D (p.Asp101Asp), rs1339928503, gnomAD 9-97689620-A-G, CADD 12.00
- D101G (p.Asp101Gly), gnomAD 9-97689621-T-C, REVEL 0.70, MetaLR 0.57
- Y102* (p.Tyr102Ter), 1000Genomes rs199710643, ExAC rs199710643, gnomAD rs199710643, CADD 24.60, Likely benign
- Y102Y (p.Tyr102Tyr), rs199710643, gnomAD 9-97689617-A-G, CADD 8.07
- V103I (p.Val103Ile), Ensembl rs1828821820, REVEL 0.19, CADD 9.05
- V103A (p.Val103Ala), gnomAD 9-97689615-A-G, REVEL 0.19, MetaLR 0.23
- I104I (p.Ile104Ile), rs1448930814, gnomAD 9-97689611-T-G, CADD 10.70
- C105* (p.Cys105Ter), rs138536873, ClinGen CA374187845, ClinVar RCV001883644, ESP rs138536873, Pathogenic
- C105Y (p.Cys105Tyr), rs1286103706, ClinGen CA374187847, ClinVar RCV002767368, Ensembl rs1286103706, REVEL 0.92, CADD 25.90, Uncertain significance, Inborn genetic diseases
- C105C (p.Cys105Cys), rs138536873, gnomAD 9-97689608-G-A, CADD 12.20
- E106K (p.Glu106Lys), rs372447411, ESP rs372447411, ExAC rs372447411, TOPMed rs372447411, REVEL 0.44, CADD 23.80, Variant assessed as somatic; moderate impact.
- E106E (p.Glu106Glu), rs1317639909, gnomAD 9-97689605-T-C, CADD 15.50
- p.Glu107 Cys108insTer, rs772081070, gnomAD 9-97689600-C-CATT, CADD 33.00
- C108F (p.Cys108Phe), rs104894131, ClinGen CA251648, ClinVar RCV000001048, ClinVar RCV005055500, REVEL 0.92, CADD 26.60, Likely pathogenic, Xeroderma pigmentosum group A; Xeroderma pigmentosum
- C108Y (p.Cys108Tyr), rs104894131, ClinGen CA374187825, ClinVar RCV000492893, ClinVar RCV000672811, REVEL 0.93, CADD 26.20, Conflicting interpretations, not provided; Xeroderma pigmentosum; Xeroderma pigmentosum group A
- G109E (p.Gly109Glu), ExAC rs761457416, TOPMed rs761457416, gnomAD rs761457416, REVEL 0.45, CADD 22.50
- G109R (p.Gly109Arg), gnomAD rs1398242554, REVEL 0.62, CADD 26.60
- G109G (p.Gly109Gly), rs1828820303, gnomAD 9-97689596-C-T, CADD 9.36
- K110E (p.Lys110Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E111* (p.Glu111Ter), rs769255883, ClinGen CA5148841, ClinVar RCV000674100, ClinVar RCV001194216, CADD 40.00, Pathogenic
- E111K (p.Glu111Lys), ExAC rs769255883, TOPMed rs769255883, gnomAD rs769255883, REVEL 0.28, CADD 23.10, Pathogenic
- E111Q (p.Glu111Gln), ExAC rs769255883, TOPMed rs769255883, gnomAD rs769255883, Pathogenic
- F112S (p.Phe112Ser), rs886039226, ClinGen CA10587998, ClinVar RCV000254511, Ensembl rs886039226, Xeroderma pigmentosum group a
- F112F (p.Phe112Phe), rs1373475991, gnomAD 9-97689587-A-G, CADD 11.10
- M113I (p.Met113Ile), TOPMed rs1828819561, gnomAD rs1828819561, REVEL 0.70, CADD 25.70
- M113R (p.Met113Arg), rs748286715, gnomAD 9-97689583-CCA-C, CADD 34.00
- M113K (p.Met113Lys), gnomAD 9-97689585-A-T, REVEL 0.66, MetaLR 0.55
- D114G (p.Asp114Gly), TOPMed rs1442427159, gnomAD rs1442427159, REVEL 0.95, CADD 33.00
Public XPA analysis runs
- XPA analysis run — XPA (558 variants) — completed 2026-08-19